Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Koffiekamer  /  Omega Diagnostics Group [ODX] - Ready to Launch the Rocket

Ontvang nu dagelijks onze kooptips!

word abonnee

Koffiekamer« Terug naar discussie overzicht

Omega Diagnostics Group [ODX] - Ready to Launch the Rocket

454 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 23 »» | Laatste | Omlaag ↓
  2. TheBiG 13 november 2020 08:17
    AbC-19TM: Response to Media

    e note the recent press speculation around the UK-RTC AbC-19TM assay and its performance. We are grateful to the authors for providing access to their data in the BMJ paper which we have reviewed.

    We believe the press articles and related BMJ report puts a spotlight on the different types of antibody testing available and what their applications are, and we very much welcome this.

    Our AbC-19TM IgG lateral flow assay is targeted at IgG antibodies to the full spike protein of SARS-CoV-2 (COVID19) to indicate a measure of immune response (aligned with neutralizing antibodies) and differs from other antibody tests, some of which our assay has been compared against (incorrectly in our view). Assays measuring IgM and IgG to the nucleocapsid (as used in this study) may be useful to show previous infection but have no place in understanding the levels of immunity producing antibodies (this requires measurement of IgG to Spike) as generated naturally or via vaccination.

    We do have some concerns with the BMJ research report and modelling methodology, and we provide details below. However, the Department for Health & Social Care (DHSC) reviewed in detail the Public Health England (PHE) report on the UK-RTC AbC-19TM assay prior to ordering kits and has provided the following statement:

    “This report shows these tests are approved for use in surveillance studies, which is what they were purchased for.

    “They were never intended for, and have never been issued for widespread public use and it is misleading and unnecessarily inflammatory to purposefully ignore this fact in the report.

    “This robust evaluation was carried out by PHE at the Department’s request before any purchase was made, and PHE approved the test for use in surveillance studies.”

    Our customer, DHSC, is satisfied with the performance of the test, as is the UK-RTC, and will continue to use and roll out the use of the product. Public Health England conducted an evaluation at the DHSC’s request, prior to DHSC purchasing the product and will continue to deploy the test for use in surveillance studies.

    www.abingdonhealth.com/abc-19-respons...
  3. TheBiG 13 november 2020 08:23
    2. An initial study2 performed at Ulster University used methods as defined by Medicines and Healthcare products Regulatory Agency (MHRA)3. Guidance from MHRA stipulated a target product profile should determine the sensitivity and specificity of antibody tests by using at least 200 samples confirmed as positive for antibodies and at least 200 samples confirmed as negative for antibodies to SARS-CoV-2. The Ulster study fulfilled this requirement and undertook a laboratory evaluation of AbC-19TM to detect SARS-CoV-2 IgG in a highly characterised cohort of known antibody positive and known antibody negative samples. This showed performance of the assay, in this well characterised known population, to give sensitivity of 97.9% and specificity of 100%.
  4. forum rang 6 mercurius-adept 13 november 2020 08:53
    UK noemt ODX oversold vanochtend:
    dailybusinessgroup.co.uk/2020/11/db-l...

    Pharmaceuticals analysts believe shares in testing firms such as Synairgen and Scottish firm Omega Diagnostics have been oversold on the back of the vaccine news from Pfizer and BioNTech.

    “While the results are very promising, we believe there was a large over-reaction in the market in response to the news,” says Mark Brewer at Pharmiweb.com.

    “It should not have been unexpected – we hoped for positive results from vaccine manufacturers this month, and we hope there is more to come, as AstraZeneca-Oxford University and Moderna are also due to announce initial results this month, and overall there are 11 vaccines in Phase III testing.

    “However, these early results do not diminish the urgent need for COVID-19 treatments and testing, which will still be required for years to come. We consider the price falls to stocks such as Synairgen (-39%), Avacta (-36%), genedrive (-38%), Omega Diagnostics (-25%) and Open Orphan (-9%) to offer good buying opportunities.

    “Even if a vaccine is perfectly effective, this will take years. Until then, the vast majority of the population will need to rely on treatments and testing for COVID-19.”

    Omega is due to report half-year figures on 30 November.
  7. TheBiG 13 november 2020 14:19
    Nou dit is toch wel goed nieuws!

    The UK-RTC, a consortium of four Lateral Flow test manufacturers, of which CIGA Healthcare is a member, has today released an overview of the use of its AbC-19 test as a companion to the Oxford/AstraZeneca Vaccine.

    "Almost 3 billion Oxford AstraZeneca Vaccines have been pre-ordered. It is expected the demand for the UK-RTC AbC-19 Rapid Tests will far exceed this number as repeat testing will be necessary to insure ongoing resistance.”

    twitter.com/cigahealthcare/status/132...
  10. TheBiG 13 november 2020 14:48
    quote:

    TheBiG schreef op 13 november 2020 14:19:

    Nou dit is toch wel goed nieuws!

    The UK-RTC, a consortium of four Lateral Flow test manufacturers, of which CIGA Healthcare is a member, has today released an overview of the use of its AbC-19 test as a companion to the Oxford/AstraZeneca Vaccine.

    "Almost 3 billion Oxford AstraZeneca Vaccines have been pre-ordered. It is expected the demand for the UK-RTC AbC-19 Rapid Tests will far exceed this number as repeat testing will be necessary to insure ongoing resistance.”

    twitter.com/cigahealthcare/status/132...
    UK RTC partner @cigahealthcare has published an overview of how the AbC-19 Rapid Test can be used alongside vaccine deployment @OmegaDiagnostic #ODX

    twitter.com/WalbrookPR/status/1327244...
  11. TheBiG 13 november 2020 15:29
    Omega Diagnostics bounces as UK RTC highlights rapid test as a companion to COVID-19 vaccines

    Shares in Omega Diagnostics (AIM: ODX) soared by as much as 20 percent in the early afternoon after rapid test consortium partner CIGA Healthcare highlighted the use of the AbC-19 test as a companion to the Oxford/AstraZenenca vaccine.

    The brief overview from CIGA highlights that the respective vaccine is designed to trigger the body to produce trimeric spike protein neutralising antibodies and the rapid AbC-19 test is designed to detect this.

    The promising update also notes:

    The AbC-19 test is approved for professional use and in trials for over-the-counter use.
    It can also be used as a companion to other vaccines such as the one from Pfizer.
    Almost 3 billion doses of the AztraZeneca vaccine have been ordered and it expects demand for its test to exceed this number across the globe. This is because it is likely people will have to be tested multiple times as the length of immunity will not be indefinite.
    It also cryptically hit backs at recent tabloid criticism by highlighting over 98% sensitivity and specificity – including a quote from Sir John Bell that states “this rapid test appears to be truly amazing.”

    The share price of ODX is currently at 55p.

    www.sharebuyers.co.uk/shares/omega-di...
  13. M c M 13 november 2020 15:44
    quote:

    Fluxx schreef op 13 november 2020 09:18:

    Voor de laatste keer vandaag bijgekocht. Mijn GAK staat inmiddels op 65 GBX.

    Zit er met meer in dan ik zou willen. Maar verwacht toch echt wel een renounce in de komende weken. Bij koers van 80GBX vliegt de helft er weer uit.
    Prima gezien Fluxx!
    Zelfde verhaal hier, gak van 105p en toen hij vanochtend doordaalde tot 44p met duidelijke ontkrachtingen en geen aanleiding tot verdere daling toch maar wat bijgekocht. GAK nu 69p, moet wel een RNS van Omega overheen komen maar als die komt staan we volgende week weer boven de 100p m.i.
  14. TheBiG 13 november 2020 15:49
    quote:

    M c M schreef op 13 november 2020 15:44:

    [...]

    Prima gezien Fluxx!
    Zelfde verhaal hier, gak van 105p en toen hij vanochtend doordaalde tot 44p met duidelijke ontkrachtingen en geen aanleiding tot verdere daling toch maar wat bijgekocht. GAK nu 69p, moet wel een RNS van Omega overheen komen maar als die komt staan we volgende week weer boven de 100p m.i.
    Let op dat nu ook nieuws vanuit AstraZeneca over het vaccin invloed gaat hebben op de koers. Positief danwel negatief!
  15. forum rang 6 mercurius-adept 13 november 2020 16:18
    quote:

    TheBiG schreef op 13 november 2020 14:19:

    Nou dit is toch wel goed nieuws!

    The UK-RTC, a consortium of four Lateral Flow test manufacturers, of which CIGA Healthcare is a member, has today released an overview of the use of its AbC-19 test as a companion to the Oxford/AstraZeneca Vaccine.

    "Almost 3 billion Oxford AstraZeneca Vaccines have been pre-ordered. It is expected the demand for the UK-RTC AbC-19 Rapid Tests will far exceed this number as repeat testing will be necessary to insure ongoing resistance.”

    twitter.com/cigahealthcare/status/132...
    mooi gezien...toch wel 'swing van de dag ' zo: van 43p GBX -5% toen naar 57p +19% nu
  17. Fluxx 15 november 2020 20:19
    Zondagavond. Tijd voor een analyse, mijn verwachting en een vleugje hoop.

    Waar staan we?
    Vrijdag 7 oktober tikten we de recordstand van 1,07 GBX aan. De belangrijkste reden was het begin van de tweede golf. Novacyt had gepiekt, en andere aandelen (ODX, GDR, ACVTA) gingen daarna mee.

    Dinsdag 27 oktober, na publiceren van de jaarcijfers stort de koers van Omega verder in. Het aandeel dipt van 92 GBX naar 72 GBX. In tegenstelling tot Novacyt deelt het bedrijf geen grote winsten of verwachtingen.

    Afgelopen maandag hakte het nieuws van Pfizer in als een bom. Het vaccin was wellicht dichterbij dan we dachten. Corona stocks kelderde 30 - 40% in waarde. ODX zakt van 76GBX naar 57GBX. Donderdag verschijnt er een pijnlijk artikel van de Guardian die ODX een flinke dreun geeft naar de 40 regionen.

    ODX reageert op de Guardian en het nieuws van Pfizer. Het stuk uit de Guardian blijkt kant nog wel te slaan. De Engelse overheid is tevreden. En de komst van een vaccin van Astra Zeneca is juist positief voor de Engels anti-body variant. Want ze kunnen op grote schaal de testen met de vaccins meeleveren.

    Vrijdag verandert het sentiment, en stijgt het terug naar 56GBX

    Mijn verwachting
    We gaan maandag verder stijgen. En mocht er al nieuws komen van Astra Zeneca, dan kan dit mogelijk een flinke versneller zijn terug naar de 100GBX regionen.

    Mijn vleugje hoop
    Zodra officiele bevestiging komt van grote orders / uk contract of AstraZeneca contract, kán dit aandeel door naar de 200-300GBX. Met uitzonderlijke potentie om zelfs de 500GBX nog te bereiken. Dit laatste, is wellicht meer hoop dan verwachting. Maar he, een mens moet kunnen dromen.

    Alvast een fijne week toegewenst. En hopelijk staat de koers vrijdag op 100GBX.

  18. Wiz@rD 15 november 2020 21:14
    AstraZeneca initial pre order of 3bn Covid-19 vaccines will be used with #ODX Antibody tests.
    This is going global for this tiny company & play a very important role to fight against this virus.
    We will be looking at many multiples upside..... THE NEXT COVID MULTIBAGGER!

    Van op het novacyt forum
454 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 23 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 879,71 +0,10%
EUR/USD 1,0685 -0,24%
FTSE 100 8.164,91 +0,54%
Germany40^ 17.923,90 -0,05%
Gold spot 2.298,09 +0,54%
NY-Nasdaq Composite 15.605,48 -0,33%

Stijgers

VIVORY...
+9,57%
ForFar...
+7,85%
ING
+7,56%
AMG Cr...
+5,15%
Van La...
+3,75%

Dalers

BAM
-11,16%
Alfen ...
-5,03%
BESI
-4,62%
PostNL
-3,24%
ASML
-2,59%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!